PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic …

AO Sartor, MJ Morris, KN Chi, JS De Bono, ND Shore… - 2022 - ascopubs.org
TPS211 Background:[177Lu] Lu-PSMA-617 (177Lu-PSMA-617) is a high-affinity prostate-
specific membrane antigen (PSMA)-targeted radioligand therapy that delivers β-particle …
被引用次数：22 相关文章

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate …

MJ Morris, D Castellano, K Herrmann, JS de Bono… - The Lancet, 2024 - thelancet.com
Summary Background [177 Lu] Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic
progression-free survival and overall survival in patients with metastatic castration-resistant …
被引用次数：17 相关文章 所有 6 个版本

TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.

M Hofman, L Emmett, JA Violet, NJ Lawrence… - 2019 - ascopubs.org
TPS332 Background: Lutetium-177 [177Lu]-PSMA-617 is a novel radiolabelled small
molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), which …
被引用次数：7 相关文章

VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA …

AO Sartor, MJ Morris, BJ Krause - 2019 - ascopubs.org
TPS5099 Background: The novel therapeutic drug 177Lu-PSMA-617 is a prostate specific
membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment …
被引用次数：27 相关文章 所有 2 个版本

VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA …

AO Sartor, MJ Morris, R Messman, BJ Krause - 2020 - ascopubs.org
TPS259 Background: The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific
membrane antigen (PSMA) targeting agent that is used to deliver radionuclide therapy for …
被引用次数：37 相关文章 所有 2 个版本
[PDF] annalsofoncology.org

LBA13 Phase III trial of [177Lu] Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

O Sartor, DEC Gauna, K Herrmann… - Annals of …, 2023 - annalsofoncology.org
Background [177 Lu] Lu-PSMA-617 (177 Lu-PSMA-617) prolongs rPFS and OS in patients
(pts) with mCRPC and prior ARPI and taxane therapy. PSMAfore (NCT04689828) examined …
被引用次数：64 相关文章

Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant …

S Ballal, MP Yadav, S Satapathy, S Raju… - European Journal of …, 2023 - Springer
Purpose Despite the existence of various treatment options, the prognosis for patients with
metastatic castration-resistant prostate cancer (mCRPC) remains unfavorable. One potential …
被引用次数：13 相关文章 所有 3 个版本
[PDF] monash.edu

TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical …

MS Hofman, L Emmett, J Violet, A Y. Zhang… - BJU …, 2019 - Wiley Online Library
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …
被引用次数：148 相关文章 所有 7 个版本

Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment …

L Emmett, M Crumbaker, B Ho, K Willowson… - Clinical genitourinary …, 2019 - Elsevier
Abstract Background 177 Lu–PSMA-617 (Lu-PSMA) is an emerging therapy in men with
metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential …
被引用次数：176 相关文章 所有 6 个版本
[HTML] nejm.org

Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer

O Sartor, J De Bono, KN Chi, K Fizazi… - … England Journal of …, 2021 - Mass Medical Soc
Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
被引用次数：1880 相关文章 所有 14 个版本